Immunic Secures U.S. Patent Allowance for Novel Vidofludimus Calcium Formulation

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biotechnology company, announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a specific polymorph of vidofludimus calcium (IMU-838). This marks a significant milestone in the protection of Immunic's leading, late-stage compound, designed for the treatment of chronic inflammatory and autoimmune diseases. The patent, which was already secured in several other countries, is set to reinforce the company’s intellectual property framework until at least 2039 in the United States and internationally until 2039, with potential further extensions.

Daniel Vitt, Ph.D., CEO and President of Immunic, highlighted the importance of this achievement in bolstering the proprietary protections around vidofludimus calcium, particularly emphasizing its relevance in the ongoing clinical trials targeting multiple sclerosis. The polymorph and its production method are now under patent safeguard, adding to the comprehensive multilayered strategy aimed at extending the exclusivity of Immunic's asset. With eight patent families covering vidofludimus calcium, Immunic demonstrates a robust commitment to securing its innovative therapies.

Vidofludimus calcium stands out as an investigational oral treatment with promising neuroprotective and immuno-modulatory properties, positioning it as a potential next-generation solution for multiple sclerosis among other diseases. Its distinctive action mechanism offers hope for efficacy with an attractive safety profile. The bolstering of Immunic’s patent portfolio underscores the company’s strides in innovation and its dedication to securing and advancing its pipeline of treatments for chronic diseases.